financetom
Business
financetom
/
Business
/
Patagonia Gold Up 8.9% As Calcatreu Construction Advances Toward Leaching
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Patagonia Gold Up 8.9% As Calcatreu Construction Advances Toward Leaching
Mar 10, 2026 11:27 PM

10:46 AM EST, 12/29/2025 (MT Newswires) -- Patagonia Gold ( HGLD ) shares rose 8.9% on Monday after it said that construction of the Calcatreu project, its flagship project in the Province of Rio Negro, Argentina, started in the first quarter of 2025 and is advancing toward first leaching, which it expects to start during Q1 of 2026.

The company said mining activities started in August 2025 with the removal of topsoil and the first blast was made in September 2025. Mineralized material is being stockpiled in the crushing area and processing will start soon with a view to placing the material on the leach pad during January 2026.

It said that the total measured and indicated mineral resources are estimated at 9.84 million tonnes at an average grade 2.11 grams per tonne (g/t) gold and 19.8 g/t silver, yielding 669 thousand ounces of gold and 6.3 million ounces of silver. The first section of the leach pad, necessary to start leaching, has been completed and during January 2026, electric leak location tests will be performed.

The chemical storage facility, with capacity to hold 120 tonnes of product, was completed in December 2025, and on Dec. 23, 80 tonnes arrived on site and is being stored on the project premises. The company intends to certify the project with the Cyanide Code and a visit by one of their auditors is planned for early January 2026.

Shares of the company were last seen up $0.035 at $0.43 on the TSX Venture Exchange.

Price: 0.43, Change: +0.04, Percent Change: +8.86

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Rise Pre-Bell Tuesday
Sector Update: Consumer Stocks Rise Pre-Bell Tuesday
Dec 31, 2024
08:51 AM EST, 12/31/2024 (MT Newswires) -- Consumer stocks were rising in Tuesday's pre-bell hours, with The Consumer Staples Select Sector SPDR Fund ( XLP ) up 0.3% and The Consumer Discretionary Select Sector SPDR Fund ( XLY ) was 0.5% higher. Vera Bradley ( VRA ) shares were up over 2% after the company's largest shareholder, Fund 1 Investments,...
Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says
Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says
Dec 31, 2024
08:41 AM EST, 12/31/2024 (MT Newswires) -- Sangamo Therapeutics' ( SGMO ) cash on its balance sheet remains an overhang following Pfizer's ( PFE ) decision to terminate a hemophilia A gene therapy collaboration with the company, Truist Securities said in a Monday note. The partnership and license agreement between the two companies are anticipated to close in Q1 next...
Merck wins UK approval for lung disease drug acquired in $11 bln deal
Merck wins UK approval for lung disease drug acquired in $11 bln deal
Dec 31, 2024
Dec 31 (Reuters) - UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's ( MRK ) therapy to treat a rare lung condition, marking another win for the drugmaker's potential blockbuster. The therapy, sotatercept, received U.S. approval in March 2024 and is sold under the brand name Winrevair. It is also approved in European Union...
Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug
Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug
Dec 31, 2024
08:44 AM EST, 12/31/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) shares fell more than 6% in pre-market trading Tuesday after the company said it was considering options for its drug candidate paxalisib after the US Food and Drug Administration discouraged an accelerated approval process for the potential glioblastoma treatment. The company said a July study of the drug...
Copyright 2023-2026 - www.financetom.com All Rights Reserved